Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
BMC Musculoskelet Disord. 2024 Nov 25;25(1):953. doi: 10.1186/s12891-024-07992-z.
One of the main purposes of clinical treatment for adhesive shoulder capsulitis is pain relief. However, patients often fail to achieve a satisfactory therapeutic response. This study aims to evaluate the impact of a combination therapy involving buprenorphine transdermal patch and celecoxib capsules on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis (ASC).
This retrospective observational study consecutively enrolled patients with primary ASC from our hospital Outpatient Department between April 2018 and June 2020. The primary outcome was pain evaluated using the visual analog scale (VAS) score. Secondary outcomes included functional improvement evaluated using the Constant-Murley Shoulder (CMS) score, as well as satisfaction and adverse reactions.
A total of 198 patients were enrolled and categorized into the celecoxib capsule group (n = 72), buprenorphine transdermal patch group (n = 65), and buprenorphine transdermal patch + celecoxib capsule group (n = 61). Patients treated with buprenorphine transdermal patch + celecoxib capsule have the lowest VAS scores and highest CMS scores at 1, 4, 8 and 12 weeks after treatment (all P < 0.001). Furthermore, there were no significant differences in adverse reactions (P = 0.296) among the three groups. The satisfaction of patient with percutaneous buprenorphine transdermal patch + celecoxib capsule was significantly higher than patients with celecoxib capsules or percutaneous buprenorphine transdermal patch (both P < 0.001).
The combination of buprenorphine transdermal patch with celecoxib capsule may result in good analgesic efficacy and functional improvement in patients with primary ASC.
Not applicable.
粘连性肩关节囊炎的主要临床治疗目的之一是缓解疼痛。然而，患者往往无法获得满意的治疗反应。本研究旨在评估丁丙诺啡透皮贴剂联合塞来昔布胶囊治疗原发性粘连性肩关节囊炎（ASC）患者改善肩部疼痛和功能的效果。
本回顾性观察性研究连续纳入了 2018 年 4 月至 2020 年 6 月我院门诊原发性 ASC 患者。主要结局是使用视觉模拟评分（VAS）评估疼痛。次要结局包括使用 Constant-Murley 肩部评分（CMS）评估功能改善，以及满意度和不良反应。
共纳入 198 例患者，分为塞来昔布胶囊组（n=72）、丁丙诺啡透皮贴剂组（n=65）和丁丙诺啡透皮贴剂+塞来昔布胶囊组（n=61）。治疗后 1、4、8 和 12 周，丁丙诺啡透皮贴剂+塞来昔布胶囊组患者的 VAS 评分最低，CMS 评分最高（均 P<0.001）。三组患者不良反应无显著差异（P=0.296）。丁丙诺啡透皮贴剂+塞来昔布胶囊组患者的满意度显著高于塞来昔布胶囊组或丁丙诺啡透皮贴剂组（均 P<0.001）。
丁丙诺啡透皮贴剂联合塞来昔布胶囊可能对原发性 ASC 患者具有良好的镇痛效果和功能改善作用。
不适用。
